FDA approves Lymphoseek for lymph node mapping

03/13/2013 | Medscape (free registration)

The FDA has approved Navidea Biopharmaceuticals' radioactive tracer Lymphoseek for breast cancer and melanoma intraoperative lymphatic mapping. The FDA said the tracer is the first agent for lymph node mapping to gain approval in more than three decades. "Removal and pathologic examination of lymph nodes draining a primary tumor is an important diagnostic evaluation for some patients with breast cancer or melanoma," said Dr. Shaw Chen of the FDA Center for Drug Evaluation and Research.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD